Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) went up by 12.57% from its latest closing price compared to the recent 1-year high of $57.13. The company’s stock price has collected 9.53% of gains in the last five trading sessions.
Is It Worth Investing in Harmony Biosciences Holdings Inc. (NASDAQ :HRMY) Right Now?
Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) scored a price-to-earnings ratio above its average ratio, recording 68.93 x from its present earnings ratio. Opinions of the stock are interesting as 6 analysts out of 8 who provided ratings for Harmony Biosciences Holdings Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $59.63, which is $4.2 above the current price. HRMY currently public float of 47.17M and currently shorts hold a 9.91% ratio of that float. Today, the average trading volume of HRMY was 520.52K shares.
HRMY’s Market Performance
HRMY stocks went up by 9.53% for the week, with a monthly jump of 6.58% and a quarterly performance of 22.88%, while its annual performance rate touched 108.03%. The volatility ratio for the week stands at 4.69% while the volatility levels for the past 30 days are set at 5.06% for Harmony Biosciences Holdings Inc. The simple moving average for the period of the last 20 days is 5.36% for HRMY stocks with a simple moving average of 28.30% for the last 200 days.
Analysts’ Opinion of HRMY
Many brokerage firms have already submitted their reports for HRMY stocks, with Goldman repeating the rating for HRMY by listing it as a “Neutral.” The predicted price for HRMY in the upcoming period, according to Goldman is $55 based on the research report published on July 13th of the current year 2022.
Mizuho, on the other hand, stated in their research note that they expect to see HRMY reach a price target of $64. The rating they have provided for HRMY stocks is “Buy” according to the report published on July 07th, 2022.
Cantor Fitzgerald gave a rating of “Overweight” to HRMY, setting the target price at $63 in the report published on April 14th of the current year.
HRMY Trading at 14.64% from the 50-Day Moving Average
After a stumble in the market that brought HRMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.99% of loss for the given period.
Volatility was left at 5.06%, however, over the last 30 days, the volatility rate increased by 4.69%, as shares surge +5.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +41.63% upper at present.
During the last 5 trading sessions, HRMY rose by +9.53%, which changed the moving average for the period of 200-days by +44.17% in comparison to the 20-day moving average, which settled at $52.74. In addition, Harmony Biosciences Holdings Inc. saw 29.97% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at HRMY starting from Nielsen Jack, who sale 40,087 shares at the price of $55.19 back on Jul 18. After this action, Nielsen Jack now owns 3,375,378 shares of Harmony Biosciences Holdings Inc., valued at $2,212,402 using the latest closing price.
Nielsen Jack, the Director of Harmony Biosciences Holdings Inc., sale 5,773 shares at $55.04 during a trade that took place back on Jul 13, which means that Nielsen Jack is holding 3,415,465 shares at $317,746 based on the most recent closing price.
Stock Fundamentals for HRMY
Current profitability levels for the company are sitting at:
- +28.66 for the present operating margin
- +75.79 for the gross margin
The net margin for Harmony Biosciences Holdings Inc. stands at +11.33. Equity return is now at value 28.70, with 11.80 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.29.